Expertise in epilepsy treatment: Prof. Dr. med. Hajo Hamer reinforces the scientific advisory board of cerbomed GmbH

ERLANGEN, Germany, 21.02.2012 – In Prof. Dr. Hajo Hamer the medical device company cerbomed GmbH gains a renowned expert in epileptology for its scientific advisory board.
Prof. Dr. Hamer will support cerbomed GmbH in carrying out an international multi-center study to treat drug-resistant epilepsy, using transcutaneous Vagus Nerve Stimulation (t-VNS).
Since April 1st, 2011 Prof. Dr. Hamer has been the new head of the Epilepsy Center at the University Hospital, Erlangen, and a senior physician in the neurological clinic. The emphases of his research are on the investigation of inflammable changes in epilepsy, and on optimizing the care of patients with epilepsy, among others. As part of the interdisciplinary team of the Epilepsy Center Erlangen, he is responsible for treating around 3,000 patients. One of the main emphases of his clinical work is the therapy of hard-to-treat epilepsies.
"In more than 30 percent of all epilepsy patients undergoing an anticonvulsive therapy there is no significant decrease in the frequency of seizures. It is therefore important to explore new forms of therapy. Transcutaneous Vagus Nerve Stimulation could represent a new, non-invasive therapy option for treating drug-resistant epilepsy", says Prof. Dr. Hamer.
"We are very pleased that Prof. Dr. Hamer is supporting us in conducting the multi-center study, which will examine the effectiveness and safety of t-VNS in 70 patients", explains Prof. Dr. Jens Ellrich, Chief Medical Officer at cerbomed GmbH.
Cerbomed GmbH will introduce the t-VNS therapy at the 51st annual conference of the German Society for Epileptology e.V. in Stuttgart, between February 29th and March 3rd, 2012.

About NEMOS
Transcutaneous Vagus Nerve Stimulation with NEMOS uses the fact that a branch of the vagus nerve is located directly under the skin in areas of the outer ear and therefore can be stimulated through the skin (transcutaneously) with electrical impulses. For t-VNS cerbomed developed and patented a special stimulator and a dedicated ear electrode. The stimulator, which is connected with the ear electrode, sends out the electrical impulses.
The t-VNS therapy is addressed to patients suffering from various difficult to treat neurological and psychiatric diseases. With NEMOS a targeted stimulation of the vagus nerve gets possible without the need of a surgery.
The German market entry for NEMOS is planned for the third quarter of 2012. NEMOS will then be available for patients suffering from hard-to-treat epilepsies and depressions.

Cerbomed GmbH is an innovative medical device company that concentrates on researching, developing and producing new technologies and products for neuromodulation. The company’s focus is on transcutaneous Vagus Nerve Stimulation (t-VNS), which may offer an attractive therapy option for patients with hard to treat neurological and psychiatric illnesses.
In March 2010 cerbomed received the European clearance (CE mark) for the transcutaneous vagus nerve stimulator NEMOS. In early 2012 two clinical studies will be starting regarding the effectiveness of t-VNS in patients with drug-resistant epilepsy and chronic migraine.

cerbomed GmbH
Dr. Martin Hyca, Director Marketing
Henkestrasse 91
DE-91052 Erlangen
+49 9131 9202 76 30
martin.hyca@cerbomed.com

This release was published on openPR.